Which oral systemic medication is recommended for treating psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Systemic Medications for Psoriasis

Methotrexate is the recommended first-line oral systemic medication for moderate to severe psoriasis, with a typical dosage of 7.5-25 mg weekly, administered orally or subcutaneously. 1

Primary Recommendation: Methotrexate

The 2020 Joint AAD-NPF Guidelines provide a Grade A recommendation for methotrexate in treating moderate to severe psoriasis in adults 1. This represents the strongest evidence-based recommendation among oral systemic therapies.

Dosing and Administration

  • Standard dose range: 7.5-25 mg weekly 1
  • Route options: Oral or subcutaneous (SC route shows superior efficacy for achieving PASI75 and PASI90 responses with fewer adverse events) 2
  • Consider a test dose in patients with impaired kidney function 1
  • Mandatory folic acid supplementation to reduce GI and hepatic adverse effects (though large doses may reduce methotrexate efficacy) 1

Monitoring Requirements

Baseline assessment:

  • Noninvasive liver fibrosis assessment (NOT liver biopsy)
  • Screen for hepatotoxicity risk factors: diabetes, obesity, nonalcoholic fatty liver disease, alcohol use >1 drink/day for women or >2 drinks/day for men, hepatitis B/C, family history of inheritable liver disease 1

Ongoing monitoring:

  • Liver function tests every 3-6 months
  • For abnormal elevations: repeat in 2-4 weeks; if persistent, refer to GI
  • Annual hepatology referral or transient elastography if baseline abnormalities present 1

Alternative Oral Agents

Cyclosporine

  • Use for: Rapid disease control (faster onset than methotrexate)
  • Limitation: Not suitable for long-term use due to nephrotoxicity and hypertension risk
  • Contraindications: Renal insufficiency, uncontrolled hypertension, prior PUVA treatment, systemic malignancy 1

Acitretin

  • Particularly effective for: Erythrodermic psoriasis, generalized pustular psoriasis, palmoplantar psoriasis (84% improvement rate in pustular variants) 1
  • Dose range: 10-50 mg daily 1
  • Major advantage: Not immunosuppressive 1
  • Critical limitation: Women cannot consider pregnancy for 3 years after discontinuation 1
  • Combination benefit: Can reduce phototherapy doses by 30-50% when combined with UVB 1

Apremilast (Phosphodiesterase-4 Inhibitor)

  • FDA-approved for psoriasis 3
  • Recent trend data: Now prescribed to 52.5% of patients starting oral therapy, largely replacing cyclosporine and acitretin due to superior safety profile 4
  • Advantage: Better continuation rates than cyclosporine 4

Tofacitinib (JAK Inhibitor)

  • NOT FDA-approved for psoriasis (approved only for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis) 1
  • Off-label dosing: 5 mg or 10 mg twice daily 1
  • Critical safety requirements before initiation 1:
    • Lymphocyte count must be ≥500 cells/mm³
    • Absolute neutrophil count ≥1000 cells/mm³
    • Hemoglobin ≥9 g/dL
  • Mandatory: Shingrix vaccination before starting 1
  • Cannot combine with: Azathioprine, cyclosporine, or biologics 1

Clinical Decision Algorithm

For moderate to severe plaque psoriasis:

  1. Start with methotrexate (Grade A evidence) unless contraindicated 1
  2. Choose subcutaneous over oral route when possible for better efficacy and tolerability 2
  3. Screen for hepatotoxicity risk factors before initiating 1

Consider alternatives when:

  • Acitretin: Patient has pustular/erythrodermic variants, or needs non-immunosuppressive option 1
  • Apremilast: Patient prioritizes safety profile over maximal efficacy 4
  • Cyclosporine: Need rapid control for acute flare (short-term only) 1

Critical Pitfalls to Avoid

  1. Do NOT perform baseline liver biopsy for methotrexate—use noninvasive fibrosis assessment instead 1
  2. Do NOT combine acitretin with tetracyclines (both increase intracranial pressure) 1
  3. Do NOT prescribe tofacitinib without checking baseline cell counts and ensuring proper vaccinations 1
  4. Do NOT forget the 3-year pregnancy restriction with acitretin in women of childbearing potential 1
  5. Methotrexate is less effective than biologics (adalimumab, infliximab) for cutaneous psoriasis—consider biologics if inadequate response 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.